Announcement

Collapse
No announcement yet.

Emerg Infect Dis. R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Emerg Infect Dis. R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.

    [Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]


    Emerg Infect Dis. 2013 Sep;19(9):1521-4. doi: 10.3201/eid1909.130724.

    R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.

    Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV.


    Abstract

    Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.

    KEYWORDS: H7N9, R292K, antimicrobial resistance, antiviral resistance, avian influenza, influenza, neuraminidase inhibitor, oseltamivir, recombinant neuraminidase, viruses, zanamivir


    PMID: 23965618 [PubMed - in process]


    -
    -------
Working...
X